Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy

BACKGROUND: Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled corticosteroid (ICS)/long-acting beta(2) agonist (LABA) treatment approved in the United States, Canada and Europe for the long-term maintenance therapy of COPD. We report data from mixed treatment comparisons (M...

Descripción completa

Detalles Bibliográficos
Autores principales: Stynes, Gillian, Svedsater, Henrik, Wex, Jaro, Lettis, Sally, Leather, David, Castelnuovo, Emanuela, Detry, Michelle, Berry, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339422/
https://www.ncbi.nlm.nih.gov/pubmed/25849223
http://dx.doi.org/10.1186/s12931-015-0184-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339422/
https://www.ncbi.nlm.nih.gov/pubmed/25849223
http://dx.doi.org/10.1186/s12931-015-0184-8

Ejemplares similares